LivaNova plc Aktie
LivaNova plc Aktie
Was spricht für und gegen LivaNova plc in den nächsten Jahren?
Pro
Kontra
Rendite von LivaNova plc im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
LivaNova plc | - | 4,94 % | 0,00 % | 19,72 % | 8,97 % | -25,00 % | -17,74 % |
Neogen Corp. | -2,65 % | 0,00 % | -21,99 % | -28,57 % | -39,89 % | -72,15 % | -57,43 % |
Bio-Rad Labs Inc. A | 1,13 % | -2,42 % | -19,54 % | -37,00 % | -12,19 % | -51,81 % | - |
Merit Medical Systems | 0,73 % | 2,22 % | -1,43 % | -6,12 % | 1,47 % | 33,98 % | 42,55 % |
Kommentare
News
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a
LivaNova to Announce First-Quarter 2024 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation